Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Single-cell multiomic analysis of mesenchymal cells reveals molecular signatures and regulators of lung allograft fibrosis
Lu Lu, A. Patrick McLinden, Natalie M. Walker, Ragini Vittal, Yichen Wang, Fatemeh Fattahi, Stephen T. Russell, Michael P. Combs, Joshua D. Welch, Vibha N. Lama
Lu Lu, A. Patrick McLinden, Natalie M. Walker, Ragini Vittal, Yichen Wang, Fatemeh Fattahi, Stephen T. Russell, Michael P. Combs, Joshua D. Welch, Vibha N. Lama
View: Text | PDF
Research Article Genetics Pulmonology

Single-cell multiomic analysis of mesenchymal cells reveals molecular signatures and regulators of lung allograft fibrosis

  • Text
  • PDF
Abstract

Survival after lung transplantation is limited by chronic, progressive graft failure, termed chronic lung allograft dysfunction (CLAD). Graft-resident mesenchymal cells (MCs) drive CLAD pathogenesis and exhibit stable dysregulated signaling, yet the transcriptomic and epigenomic drivers underlying this fibrogenic transformation remain elusive. We used single-cell multiomic profiling to characterize gene expression and chromatin accessibility in MCs isolated from bronchoalveolar lavage fluid of lung transplant recipients with and without CLAD, collected early after transplantation or after disease onset. MCs obtained after CLAD onset demonstrated a distinct transcriptomic signature compared with non-CLAD controls, enabling classification of disease status at the single-cell level with greater than 98% accuracy using signature genes. Chromatin accessibility analyses identified enrichment of CCAAT-enhancer-binding protein family transcription factors, specifically CEBPD, in CLAD MCs. MCs early after transplantation showed minimal accessibility differences, suggesting that CEBPD-associated regulatory changes emerge over time. Integration analyses identified 8 MC states and a CLAD-specific shift toward a fibrotic state. CEBPD, SOX4, and FOXP2 were identified as putative regulators of this state with substantial overlap in predicted targets. Targeting CEBPD reversed fibrotic phenotypes of CLAD MCs (decreased ECM expression, contractility, proliferation, and migration). Together, these data provide insights into transcriptomic and epigenomic changes in posttransplant MCs, facilitating the nomination of biomarkers and therapeutic targets.

Authors

Lu Lu, A. Patrick McLinden, Natalie M. Walker, Ragini Vittal, Yichen Wang, Fatemeh Fattahi, Stephen T. Russell, Michael P. Combs, Joshua D. Welch, Vibha N. Lama

×

Figure 6

CEBPD knockdown partially reverts CLAD gene expression signature.

Options: View larger image (or click on image) Download as PowerPoint

CEBPD knockdown partially reverts CLAD gene expression signature.
(A) R...
(A) RT-qPCR analysis of expression of CEBPD relative to GAPDH in CLAD MCs treated with scrambled or CEBPD siRNA. Comparisons were conducted using unpaired, 2-tailed Student’s t test. *P < 0.05. (B) Protein expression of CEBPD in CLAD MCs treated with scrambled or CEBPD siRNA as measured by Western blot analysis. (C) Volcano plot illustrating the differentially expressed genes following CEBPD knockdown in CLAD MCs. The x-axis represents the log2(fold change), and the y-axis represents the –logFDR. Genes that are significantly upregulated (log2FC > 0.5, adj. P < 0.05) are marked in red, while significantly downregulated genes (log2FC < –0.5, adj. P < 0.05) are marked in blue. Non-significant genes are shown in gray. Gene symbols highlighted with texts are part of the CLAD signature from Figure 2E. (D) Bar plot showing the total expression of the upregulated CLAD signature genes between CLAD MCs treated with scrambled (blue) or CEBPD (orange) siRNA. The x-axis is the cell line; control and knockdown samples from the same line are shown as adjacent bars. The y-axis represents the log sum of counts per million. (E) GO enrichment analysis showing downregulation of ECM-related genes after CEBPD knockdown. (F) KEGG pathway enrichment analysis showing downregulation of glutathione metabolism–related genes after CEBPD knockdown.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts